Amplia Therapeutics Limited
INNMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -15% | 274.3% | -40% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.4% | 90.1% | 93.8% | 99.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -179.2% | -102.4% | -610.7% | -183.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -173.7% | -101.1% | -524.8% | -183.7% |
| EPS Diluted | -0.021 | -0.023 | -0.032 | -0.025 |
| % Growth | 7.8% | 28% | -28.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |